In phase 3 studies, alemtuzumab demonstrated efficacy and safety in patients with relapsing-remitting multiple sclerosis. In an interview with touchNEUROLOGY, Prof. Bart Van Wijmeersch (Universiteit Hasselt and Rehabilitation and MS-Centre Pelt, Belgium) talks through the aims of the alemtuzumab post-authorization safety study, key findings, and insights gained regarding duration of monitoring following treatment with alemtuzumab for multiple sclerosis.
Questions:
- Â What are the aims of the alemtuzumab post-authorization safety study and what period, post-first exposure, will it cover? (00:18)
- Â What are the key findings from this interim analysis? (00:48)
- Â What insight has been gained regarding the necessary duration of monitoring following treatment with alemtuzumab for multiple sclerosis? (01:46)
- Â Have any risk factors for experiencing treatment-related adverse events with alemtuzumab been identified? (02:47)
The abstract titled ‘Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)’ (Abstract #EPR-165) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Bart Van Wijmeersch has received grant/research support from Merck, Sanofi-Genzyme and participated in advisory boards from Almirall, Actelion/Janssen, Bayer, Biogen, Celgene/BMS, Imcyse, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
